Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Gains from Investment Securities (2016 - 2024)

Historic Gains from Investment Securities for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Q4 2024 value amounting to $3.8 million.

  • Rocket Pharmaceuticals' Gains from Investment Securities changed N/A to $3.8 million in Q4 2024 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year increase of 40152.73%. This contributed to the annual value of $1.9 million for FY2024, which is 61538.46% up from last year.
  • According to the latest figures from Q4 2024, Rocket Pharmaceuticals' Gains from Investment Securities is $3.8 million.
  • Rocket Pharmaceuticals' Gains from Investment Securities' 5-year high stood at $20.2 million during Q1 2020, with a 5-year trough of -$2.9 million in Q2 2024.
  • Its 5-year average for Gains from Investment Securities is $6.8 million, with a median of $5.8 million in 2020.
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Gains from Investment Securities surged by 176656.98% in 2020, and later crashed by 11937.46% in 2024.
  • Over the past 5 years, Rocket Pharmaceuticals' Gains from Investment Securities (Quarter) stood at $6.4 million in 2020, then decreased by 18.67% to $5.2 million in 2021, then soared by 139.88% to $12.5 million in 2022, then grew by 18.75% to $14.9 million in 2023, then plummeted by 74.78% to $3.8 million in 2024.
  • Its Gains from Investment Securities stands at $3.8 million for Q4 2024, versus -$104000.0 for Q3 2024 and -$2.9 million for Q2 2024.